Morepen Lab zooms on expanding reactor capacity for API, CDMO
Morepen Laboratories is currently trading at Rs. 120.40, up by 6.70 points or 5.89% from its previous closing of Rs. 113.70 on the BSE.
The scrip opened at Rs. 116.35 and has touched a high and low of Rs. 120.35 and Rs. 114.55 respectively. So far 544410 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 120.10 on 07-Sep-2026 and a 52 week low of Rs. 33.44 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 120.10 and Rs. 100.25 respectively. The current market cap of the company is Rs. 6432.98 crore.
The promoters holding in the company stood at 35.65%, while Institutions and Non-Institutions held 2.75% and 61.59% respectively.
Morepen Laboratories has successfully completed the first phase of its manufacturing capacity expansion program ahead of the previously indicated timeline. Under this first phase, the company’s installed reactor capacity for API and CDMO has increased from 535 KL to 614 KL.
This capacity enhancement strengthens the company’s manufacturing readiness for the ongoing scale-up of commercial CDMO supplies, while also supporting its existing API business and future customer programs.
The capacity expansion plays a key role in the company’s strategy to build a larger, scalable and globally compliant manufacturing platform, focused on long-duration customer partnerships and sustained growth across its API and CDMO businesses.
